Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
UA COVID-19 National Registry: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors with DNA-Repair Defects
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 23, 2023
A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
AAML18P1 Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin &Cyclophosphamide Plus VINO-CPO Maintenance in HR-RMS
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023